drugset / Trial / NCT00761514
Evaluation of Quality of Life Changes in Puerto Rican Subjects With Active Rheumatoid Arthritis Treated With Humira
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The primary objective of this study is to evaluate quality of life changes in Puerto Rican subjects with Rheumatoid Arthritis treated with Humira (adalimumab) as their first Anti-TNF Monoclonal Antibody.
Timeline
- Start
- 2006-11
- Primary completion
- 2008-08
- Completion
- 2008-08
Outcome
Outcome not reported
Stopped (Enrollment): “The study was terminated due to low enrollment.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adalimumab | Monoclonal antibody | 40 mg | — |